Background and Need for Legislation
Approximately 1,600 American children and adolescents die
each year from cancer and, in 2024, roughly 14,910 children and
adolescents were diagnosed with cancer.\1\ In recent years, the
5-year survival rates for most childhood cancers have
improved--between 1975 and 2022, the cancer mortality rate
among children and adolescents decreased from 5.1 per 100,000
children and adolescents to 2.2 per 100,000 children and
adolescents.\2\ Though cancer outcomes have generally improved,
the rate of improvement in survival has more recently slowed
and more than one-half of pediatric cancer survivors experience
serious long-term effects of their cancer and its therapy.\3\
In addition, there remain disparities between the outcomes and
cancer-related mortality across cancer types, ultimately
requiring more research and treatment development. Combination
therapy, a treatment method that utilizes two or more
therapeutic agents, is considered a cornerstone of cancer
therapy.\4\ Combination therapies are often more effective than
single agent therapy and demonstrate lower levels of toxicity
during long-term treatment.\5\ Currently, the FDA is only
authorized to require pediatric trials of single drug cancer
treatments.
---------------------------------------------------------------------------
\1\American Cancer Society, Cancer Facts & Figures 2024 (2024),
https://www.cancer.org/
content/dam/cancer-org/research/cancer-facts-and-statistics/annual-
cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf;
see also NATIONAL INSTITUTE OF HEALTH (NIH), National Cancer Institute,
Cancer in Children and Adolescents (Aug. 27, 2024), https://
www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-
sheet.
\2\NIH, National Cancer Institute, Cancer in Children and
Adolescents (Aug. 27, 2024), https://www.cancer.gov/types/childhood-
cancers/child-adolescent-cancers-fact-sheet.
\3\Erin Butler et al., ``Recent progress in the treatment of cancer
in children,'' American Cancer Society Journals, 2021, https://
acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21665.
\4\Rexa Bayat Mokhtari et al., Combination therapy in combating
cancer, Oncotarget (Mar. 30, 2017), https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC5514969/.
\5\Yiling Wang & Audrey Minden, Current Molecular Combination
Therapies Used for the Treatment of Breast Cancer, International
Journal of Molecular Sciences (Sept. 20, 2022), https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC9569555/
#::text=Recently%2C%20combination%20
therapies%20%28in%20which%20two%20or%20more,demonstrate%20lower%20levels
%20of%20 toxicity%20during%20long-term%20treatment.
---------------------------------------------------------------------------
In addition, roughly 15 million American children are
living with a rare disease, yet 95 percent of rare diseases do
not have an FDA-approved treatment.\6\ The FDA rare pediatric
disease priority review voucher (PRV) program, which sunset
after December 20, 2024, aims to incentivize drug development
of treatments and cures for rare pediatric diseases by awarding
a priority review voucher for a qualifying drug or biological
product that targets a rare pediatric disease.\7\ Since the
program was first authorized in 2012, there have been over 60
PRVs awarded to sponsors that developed treatments for
pediatric rare diseases.\8\
---------------------------------------------------------------------------
\6\National Organization for Rare Disorders (NORD), Congress:
Reauthorize the Rare Pediatric Disease Priority Review Voucher Program
(Jul. 23, 2024), https://rarediseases.org/rare-pediatric-disease-prv-
program/.
\7\U.S. FOOD AND DRUG ADMINISTRATION, Rare Pediatric Disease
Designation and Priority Review Voucher Programs (Sept. 27, 2024),
https://www.fda.gov/industry/medical-products-rare-diseases-and-
conditions/rare-pediatric-disease-designation-and-priority-review-
voucher-
programs.
\8\Between 2012 and August 28, 2025, there have been a total of 48
Rare Pediatric Disease (RPD) PRVs issued through FDA's Center for Drug
Evaluation and Research and a total of 13 RPD PRVs issued through FDA's
Center for Biologics Evaluation and Research and published on the
Federal Register. See Notice, 79 Fed. Reg. 14055 (Mar. 12, 2014); see
also 80 Fed. Reg. 18628 (Apr. 7, 2015); 80 Fed. Reg. 18628 (Apr. 7,
2015); 80 Fed. Reg. 58489 (Sept. 29, 2015); 80 Fed. Reg. 71811 (Nov.
17, 2015); 81 Fed. Reg. 71511 (Oct. 17, 2016); 82 Fed. Reg. 12614 (Mar.
6, 2017); 82 Fed. Reg. 19052 (Apr. 25, 2017); 82 Fed. Reg. 28860 (Jun.
26, 2017); 82 Fed. Reg. 42686 (Sept. 11, 2017); 82 Fed. Reg. 59622
(Dec. 15, 2017); 83 Fed. Reg. 125 (Jan. 2, 2018); 83 Fed. Reg. 34139
(Jul. 19, 2018); 83 FR 40524 (Aug. 15, 2018); 83 Fed. Reg. 53880 (Oct.
25, 2018); 83 Fed. Reg. 64133 (Dec. 13, 2018); 84 Fed. Reg. 11985 (Mar.
29, 2019); 84 Fed. Reg. 29520 (Jun. 24, 2019); 84 Fed. Reg. 31324 (Jul.
1, 2019); 85 Fed. Reg. 3935 (Jan. 23, 2020); 85 Fed. Reg. 52354 (Aug.
25, 2020); 85 Fed. Reg. 55304 (Sept. 4, 2020); 85 Fed. Reg. 57217
(Sept. 15, 2020); 85 Fed. Reg. 57864 (Sept. 16, 2020); 85 Fed. Reg.
78859 (Dec. 7, 2020); 85 Fed. Reg. 81929 (Dec. 17, 2020); 85 Fed. Reg.
81933 (Dec. 17, 2020); 86 Fed. Reg. 9514 (Feb. 16, 2021); 86 Fed. Reg.
14125 (Mar. 12, 2021); 86 Fed. Reg. 14130 (Mar. 12, 2021); 86 Fed. Reg.
35307 (Jul. 2, 2021); 86 Fed. Reg. 59405 (Oct. 27, 2021); 87 Fed. Reg.
52782 (Aug. 29, 2022); 87 Fed. Reg. 54515 (Sept. 6, 2022); 87 Fed. Reg.
54700 (Sept. 7, 2022); 87 Fed. Reg. 61090 (Oct. 7, 2022); 87 Fed. Reg.
61090 (Oct. 7, 2022); 88 Fed. Reg. 16266 (Mar. 16, 2023); 88 Fed. Reg.
16274 (Mar. 16, 2023); 88 Fed. Reg. 19150 (Mar. 30, 2023); 88 Fed. Reg.
24806 (Apr. 24, 2023); 88 Fed. Reg. 37068 (Jun. 6, 2023); 88 Fed. Reg.
45430 (Jul. 17, 2023); 88 Fed. Reg. 61598 (Sept. 7, 2023); 88 Fed. Reg.
61600 (Sept. 7, 2023); 88 Fed. Reg. 84337 (Dec. 5, 2023); 89 Fed. Reg.
1097 (Jan. 9, 2024); 89 Fed. Reg. 1924 (Jan. 11, 2024); 89 Fed. Reg.
1925 (Jan. 11, 2024); 89 Fed. Reg. 25634 (Apr. 11, 2024); 89 Fed. Reg.
27767 (Apr. 18, 2024); 89 Fed. Reg. 42472 (May 15, 2024); 89 Fed. Reg.
42888 (May 16, 2024); 89 Fed. Reg. 68909 (Aug. 28, 2024); 89 Fed. Reg.
83023 (Oct. 15, 2024); 89 Fed. Reg. 83020 (Oct. 15, 2024); 89 Fed. Reg.
95219 (Dec. 2, 2024); 90 Fed. Reg. 2008 (Jan. 10, 2025); 90 Fed. Reg.
3880 (Jan. 15, 2025); 90 Fed. Reg. 11992 (Mar. 13, 2025); and 90 Fed.
Reg. 42018 (Aug. 28, 2025).
---------------------------------------------------------------------------
In addition, FDA currently requires certain formulations of
generic medicines to demonstrate qualitative and quantitative
sameness of inactive ingredients with their brand-name
reference product. Generic drug developers often lack
information about these inactive ingredients, which can result
in inefficiencies in agency review, slower approvals, and
delayed access of generic drugs for patients.
By extending FDA's authority to require completion of
pediatric studies of combination therapies, as well as
clarifying that Orphan Drug Exclusivity only applies to the
same approved use or indication within such rare disease or
condition, as opposed to the entire disease or condition,
reauthorizing the rare pediatric disease priority review
voucher (PRV) program, providing a technical correction to the
authorization of appropriations to support efforts at the NIH
to research and improve the safety and efficacy of medication
use for children, and establishing an FDA office in an Abraham
Accords country to facilitate innovation, the Give Kids a
Chance Act of 2025 seeks to accelerate the development of
novel, safe, and effective treatments and improve outcomes for
pediatric cancer and rare pediatric diseases. Further, allowing
the Department of Health and Human Services (HHS) to collect
and distribute registration fees itself to support the OPTN
operations, as well as increasing transparency and reducing
burdens related to generic drug approvals, will continue our
shared missions to increase organ transplant rates and improve
access to timely, cost-efficient treatments, respectively--
ultimately leading to improved health outcomes.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to expand
FDA authority related to pediatric cancer and rare disease
research and development, allow the Secretary of Health and
Human Services (HHS) to collect registration fees from OPTN
members to support the operation of the OPTN, and increase
access to generic drugs.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 1262 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 1262:
On June 24, 2025, the Subcommittee on Health
held a hearing related to H.R. 1262. The title of the
hearing was ``The Fiscal Year 2026 Department of Health
and Human Services Budget.'' The Subcommittee received
testimony from:
The Honorable Robert F. Kennedy,
Jr., Secretary, U.S. Department of Health and
Human Services.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 1262 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title; table of contents
Section 1 provides a short title of ``Give Kids a Chance
Act of 2025'' and the table of contents for this Act.
Section 2. Research into pediatric uses of drugs; additional
authorities of Food and Drug Administration regarding
molecularly targeted cancer drugs
Section 2 provides the Food and Drug Administration (FDA)
the authority to require pediatric cancer trials for new drugs
that are used in combination with active ingredients that meet
the standard of care for targeting pediatric cancer or have
been approved to treat adult cancer and are directed at
molecular targets for pediatric cancer. It would also require
the Government Accountability Office (GAO) to conduct a study
and report to Congress on the effectiveness of the requirements
outlined in this section in the development of drugs and
biological products for pediatric cancer indications.
Section 3. Ensuring completion of pediatric study requirements
Section 3 provides the FDA the authority to enforce against
companies that fail to meet pediatric study requirements. The
Secretary of the Department of Health and Human Services shall
perform due diligence before concluding failure to meet
requirements.
Section 4. FDA report on PREA enforcement
Section 4 requires the FDA to report on enforcement of the
Pediatric Research Equity Act (PREA).
Section 5. Extension of authority to issue priority review vouchers to
encourage treatments for rare pediatric diseases
Section 5 extends the FDA priority review voucher program
through September 30, 2029, to incentivize the development of
drugs for rare pediatric diseases. It also requires a study
from the GAO on the effectiveness of the pediatric PRV program.
Section 6. Limitations on exclusive approval of licensure of orphan
drugs
Section 6 clarifies that orphan drug exclusivity applies to
the approved indication, rather than the potentially broader
designation, in alignment with the FDA's interpretation.
Section 7. Program for pediatric studies of drugs
Section 7 makes a technical correction to the existing
authorization of appropriations for the National Institutes of
Health (NIH) to research studies of drugs in children.
Section 8. Organ Procurement and Transplantation Network
Section 8 allows the Secretary of Health and Human Services
to collect registration fees from any member of the Organ
Procurement Transplantation Network (OPTN) for each transplant
candidate such member places on the list and distribute these
fees to support the operation of OPTN, for a period of 3 years.
Section 9. Establishment of Abraham Accords Office within Food and Drug
Administration
Section 9 would require the Food and Drug Administration to
establish an office in an Abraham Accords country to enhance
facilitation with the agency and require the Secretary of
Health and Human Services to submit a report to Congress to
evaluate the office's progress.
Section 10. Increasing transparency in generic drug applications
Section 10 requires FDA to disclose to certain formulations
of generic drug applicants what ingredients, if any, cause a
drug to be quantitatively or qualitatively different from the
listed drug for purposes of establishing sameness in
formulation, and the specific amount of the difference.
Section 11. Medicare Improvement Fund
Section 11 adjusts the amount of funding in the Medicare
Improvement Fund from $1.804 billion to $3.047 billion.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
FEDERAL FOOD, DRUG, AND COSMETIC ACT
* * * * * * *
CHAPTER III--PROHIBITED ACTS AND PENALTIES
* * * * * * *
penalties
Sec. 303. (a)(1) Any person who violates a provision of
section 301 shall be imprisoned for not more than one year or
fined not more than $1,000, or both.
(2) Notwithstanding the provisions of paragraph (1) of this
section, if any person commits such a violation after a
conviction of him under this section has become final, or
commits such a violation with the intent to defraud or mislead,
such person shall be imprisoned for not more than three years
or fined not more than $10,000 or both.
(b)(1) Notwithstanding subsection (a), any person who
violates section 301(t) by--
(A) knowingly importing a drug in violation of
section 801(d)(1),
(B) knowingly selling, purchasing, or trading a drug
or drug sample or knowingly offering to sell, purchase,
or trade a drug or drug sample, in violation of section
503(c)(1),
(C) knowingly selling, purchasing, or trading a
coupon, knowingly offering to sell, purchase, or trade
such a coupon, or knowingly counterfeiting such a
coupon, in violation of section 503(c)(2), or
(D) knowingly distributing drugs in violation of
section 503(e)(1),
shall be imprisoned for not more than 10 years or fined not
more than $250,000, or both.
(2) Any manufacturer or distributor who distributes drug
samples by means other than the mail or common carrier whose
representative, during the course of the representative's
employment or association with that manufacturer or
distributor, violated section 301(t) because of a violation of
section 503(c)(1) or violated any State law prohibiting the
sale, purchase, or trade of a drug sample subject to section
503(b) or the offer to sell, purchase, or trade such a drug
sample shall, upon conviction of the representative for such
violation, be subject to the following civil penalties:
(A) A civil penalty of not more than $50,000 for each
of the first two such violations resulting in a
conviction of any representative of the manufacturer or
distributor in any 10-year period.
(B) A civil penalty of not more than $1,000,000 for
each violation resulting in a conviction of any
representative after the second conviction in any 10-
year period.
For the purposes of this paragraph, multiple convictions of one
or more persons arising out of the same event or transaction,
or a related series of events or transactions, shall be
considered as one violation.
(3) Any manufacturer or distributor who violates section
301(t) because of a failure to make a report required by
section 503(d)(3)(E) shall be subject to a civil penalty of not
more than $100,000.
(4)(A) If a manufacturer or distributor or any representative
of such manufacturer or distributor provides information
leading to the institution of a criminal proceeding against,
and conviction of, any representative of that manufacturer or
distributor for a violation of section 301(t) because of a
sale, purchase, or trade or offer to purchase, sell, or trade a
drug sample in violation of section 503(c)(1) or for a
violation of State law prohibiting the sale, purchase, or trade
or offer to sell, purchase, or trade a drug sample, the
conviction of such representative shall not be considered as a
violation for purposes of paragraph (2).
(B) If, in an action brought under paragraph (2) against a
manufacturer or distributor relating to the conviction of a
representative of such manufacturer or distributor for the
sale, purchase, or trade of a drug or the offer to sell,
purchase, or trade a drug, it is shown, by clear and convincing
evidence--
(i) that the manufacturer or distributor conducted,
before the institution of a criminal proceeding against
such representative for the violation which resulted in
such conviction, an investigation of events or
transactions which would have led to the reporting of
information leading to the institution of a criminal
proceeding against, and conviction of, such
representative for such purchase, sale, or trade or
offer to purchase, sell, or trade, or
(ii) that, except in the case of the conviction of a
representative employed in a supervisory function,
despite diligent implementation by the manufacturer or
distributor of an independent audit and security system
designed to detect such a violation, the manufacturer
or distributor could not reasonably have been expected
to have detected such violation,
the conviction of such representative shall not be considered
as a conviction for purposes of paragraph (2).
(5) If a person provides information leading to the
institution of a criminal proceeding against, and conviction
of, a person for a violation of section 301(t) because of the
sale, purchase, or trade of a drug sample or the offer to sell,
purchase, or trade a drug sample in violation of section
503(c)(1), such person shall be entitled to one-half of the
criminal fine imposed and collected for such violation but not
more than $125,000.
(6) Notwithstanding subsection (a), any person who is a
manufacturer or importer of a prescription drug under section
804(b) and knowingly fails to comply with a requirement of
section 804(e) that is applicable to such manufacturer or
importer, respectively, shall be imprisoned for not more than
10 years or fined not more than $250,000, or both.
(7) Notwithstanding subsection (a)(2), any person that
knowingly and intentionally adulterates a drug such that the
drug is adulterated under subsection (a)(1), (b), (c), or (d)
of section 501 and has a reasonable probability of causing
serious adverse health consequences or death to humans or
animals shall be imprisoned for not more than 20 years or fined
not more than $1,000,000, or both.
(8) Notwithstanding subsection (a), any person who violates
section 301(i)(3) by knowingly making, selling or dispensing,
or holding for sale or dispensing, a counterfeit drug, or who
violates section 301(fff)(3) by knowingly making, selling or
dispensing, or holding for sale or dispensing, a counterfeit
device, shall be imprisoned for not more than 10 years or fined
in accordance with title 18, United States Code, or both.
(c) No person shall be subject to the penalties of subsection
(a)(1) of this section, (1) for having received in interstate
commerce any article and delivered it or proffered delivery of
it, if such delivery or proffer was made in good faith, unless
he refuses to furnish on request of an officer or employee duly
designated by the Secretary the name and address of the person
from whom he purchased or received such article and copies of
all documents, if any there be, pertaining to the delivery of
the article to him; or (2) for having violated section 301(a)
or (d), if he establishes a guaranty or undertaking signed by,
and containing the name and address of, the person residing in
the United States from whom he received in good faith the
article, to the effect, in case of an alleged violation of
section 301(a), that such article is not adulterated or
misbranded, within the meaning of this Act, designating this
Act, or to the effect, in case of an alleged violation of
section 301(d), that such article is not an article which may
not, under the provisions of section 404 or 505, be introduced
into interstate commerce; or (3) for having violated section
301(a), where the violation exists because the article is
adulterated by reason of containing a color additive not from a
batch certified in accordance with regulations promulgated by
the Secretary under this Act, if such person establishes a
guaranty or undertaking signed by, and containing the name and
address of, the manufacturer of the color additive, to the
effect that such color additive was from a batch certified in
accordance with the applicable regulations promulgated by the
Secretary under this Act; or (4) for having violated section
301 (b), (c), or (k) by failure to comply with section 502(f)
in respect to an article received in interstate commerce to
which neither section 503(a) nor section 503(b)(1) is
applicable, if the delivery or proffered delivery was made in
good faith and the labeling at the time thereof contained the
same directions for use and warning statements as were
contained in the labeling at the time of such receipt of such
article; or (5) for having violated section 301(i)(2) if such
person acted in good faith and had no reason to believe that
use of the punch, die, plate, stone, or other thing involved
would result in a drug being a counterfeit drug, or for having
violated section 301(i)(3) if the person doing the act or
causing it to be done acted in good faith and had no reason to
believe that the drug was a counterfeit drug; or (6) for having
violated section 301(fff)(2) if such person acted in good faith
and had no reason to believe that use of the punch, die, plate,
stone, or other thing involved would result in a device being a
counterfeit device, or for having violated section 301(fff)(3)
if the person doing the act or causing it to be done acted in
good faith and had no reason to believe that the device was a
counterfeit device.
(d) No person shall be subject to the penalties of subsection
(a)(1) of this section for a violation of section 301 involving
misbranded food if the violation exists solely because the food
is misbranded under section 403(a)(2) because of its
advertising.
(e)(1) Except as provided in paragraph (2), whoever knowingly
distributes, or possesses with intent to distribute, human
growth hormone for any use in humans other than the treatment
of a disease or other recognized medical condition, where such
use has been authorized by the Secretary of Health and Human
Services under section 505 and pursuant to the order of a
physician, is guilty of an offense punishable by not more than
5 years in prison, such fines as are authorized by title 18,
United States Code, or both.
(2) Whoever commits any offense set forth in paragraph (1)
and such offense involves an individual under 18 years of age
is punishable by not more than 10 years imprisonment, such
fines as are authorized by title 18, United States Code, or
both.
(3) Any conviction for a violation of paragraphs (1) and (2)
of this subsection shall be considered a felony violation of
the Controlled Substances Act for the purposes of forfeiture
under section 413 of such Act.
(4) As used in this subsection the term ``human growth
hormone'' means somatrem, somatropin, or an analogue of either
of them.
(5) The Drug Enforcement Administration is authorized to
investigate offenses punishable by this subsection.
(f)(1)(A) Except as provided in subparagraph (B), any person
who violates a requirement of this Act which relates to devices
shall be liable to the United States for a civil penalty in an
amount not to exceed $15,000 for each such violation, and not
to exceed $1,000,000 for all such violations adjudicated in a
single proceeding. For purposes of the preceding sentence, a
person accredited under paragraph (2) of section 704(g) who is
substantially not in compliance with the standards of
accreditation under such section, or who poses a threat to
public health or fails to act in a manner that is consistent
with the purposes of such section, shall be considered to have
violated a requirement of this Act that relates to devices.
(B) Subparagraph (A) shall not apply--
(i) to any person who violates the requirements of
section 519(a) or 520(f) unless such violation
constitutes (I) a significant or knowing departure from
such requirements, or (II) a risk to public health,
(ii) to any person who commits minor violations of
section 519(e) or 519(g) (only with respect to
correction reports) if such person demonstrates
substantial compliance with such section, or
(iii) to violations of section 501(a)(2)(A) which
involve one or more devices which are not defective.
(2)(A) Any person who introduces into interstate commerce or
delivers for introduction into interstate commerce an article
of food that is adulterated within the meaning of section
402(a)(2)(B) or any person who does not comply with a recall
order under section 423 shall be subject to a civil money
penalty of not more than $50,000 in the case of an individual
a